It’s kind of like Coke and Pepsi. In a lot of respects, injectors have a different response depending on a patient’s anatomy and biology. They are all good products. Xeomin is a protein that doesn’t have additional molecules with it that bind the actual active molecule. Some physicians think this is better while others prefer the carrier molecules. Each is manufactured in a different way, and there are subtle differences between them. Each has its own advocates, but Botox still retains the lead in terms of number of injections. The arrival of the two new competitors has increased the amount of people getting injections; so they all are increasing their marketing because of competition.